All Posts Tagged With: "antibiotic"

ACS 200 & ACZ Nano

Linda’s comment:  I personally can not live without my ACS200 and ACZnano Zeolite….I go so far as to carry a bottle of each in my purse….
CS basic technology goes to the head of the class of effective antimicrobials for topical applications. Many of you are still not convinced that ACS 200 is the breakthrough technology in colloidal silver chemistry that we have been telling you. Please understand the principals behind ACS 200 did not get EPA approval, as a sterilant easily. This is a multi-billion dollar market making what you do about treating patients who have infections of only passing interest to investors who have put up the money to get this sterilant product approved in a highly competitive environment.

That same knowledge base brought out the Total Body Detox with ACS 200 and ACZ. These are so easy to use that if you begin to believe that your patient’s toxins are part of their health problem, you owe it to them to let them try this convenient easy, gentle, lower dose form of ZEOLITE suitable for every age, including during pregnancy and for all pets.

Remember only when you lower the total body burden of toxins do you really deal with inflammation at the core. Only then can any chelator or Zeolite detox program begin to show its true potential. With the numbers on their website supporting the fact that mercury is really being removed with the easy affordable Total Body Detox Program.

When you have a surface that must remain sterile, whether on board a cruise ship kitchen or an operating room or a dentist office, this will be the sterilant that will set the standard for a long time.  It has additional molecules to enable it to deal with dangerous surfaces like our nation’s capitol after the anthrax exposure.

With this product no building will be needlessly closed for days, weeks or months like the post office where the anthrax was shipped from with a clean-up bill in the millions.

This is vital information for you if you believe there is something to my FIGHT program and you want to eliminate the needless deaths in over 100,000 people each year where no antibiotic would work. ACS alone would have made a huge difference and with my infection program by adding VIT A, D, C, Garlic immune support etc, as clearly described on my website under infection protocols.

We should be able to save over 90% who otherwise will die with the standard drugs being used today. It is never too late to add ACS and ACZ topically and orally, the drugs will not be damaged by adding Silver. And, now we have ANTIFUNGAL ANTIVIRAL and ANTIBIOTIC effects that are real without exception even HIV, Hepatitis and Lyme!!!

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

http://www.resultsrna.com/products/steriplex_health_care_now_epa_approved.php

STERIPLEX Health Care Now EPA Approved
By David Larson, President

Powered by the leading silver technology utilized by Advanced Cellular Silver (ACS) 200®, STERIPLEX® Health Care is now the most powerful Sporicide/ Sterilant ever approved by the EPA.

As germs like MRSA, C. diff. and anthrax become increasingly life-threatening, the war on superbugs continues as biotechnology companies from around the world race to produce products that kill germs effectively, without harming people or the environment. And while consumers become ever more aware of product safety, harsh chemical disinfectants are out; safe and effective is definitely in.

STERIPLEX® Health Care (HC) is a revolutionary new Sterilant/Sporicide, which has recently received Federal EPA Registration. A paradigm shift in infection control STERIPLEX® Health Care sets new standards, killing spores in a tiny fraction of the time of competing products while remaining safe to people and the environment. Independent GLP certified laboratories have verified that STERIPLEX® Health Care destroys the most virulent pathogens including C. sporogenes and B. subtilis spores 10 to 32 times faster than other sterilant brands. With never before seen kill times, these results are truly remarkable as virulent spores are truly some of the toughest germs to kill. A sporicide will typically destroy all other germ species as well.

And just how safe is safe? STERIPLEX® Health Care is completely non-toxic, non-corrosive, non-flammable and 100% biodegradable. STERIPLEX® Health Care can safely be used as a not critical care instrument soak and to disinfect all hard surfaces. Competing sterilants have performance problems and/or serious corrosion and toxic side effects. For example, Glutaraldehyde is a widely used sterilant in medical facilities, but it is highly toxic. Because of its many adverse side effects, Glutaraldehyde was banned in Great Britain several years ago. Chlorine-based products are extremely corrosive and harmful if inhaled or swallowed. Alcohol-based products, which offer only modest antimicrobial performance, disintegrate plastics and are harmful if inhaled or swallowed.

Now consider that the new spore testing benchmarks required by the EPA to achieve sterilant (sporicidal) registration are far more rigorous today than the testing required of previously approved chemical sporicides. The new EPA spore testing protocols required STERIPLEX® Health Care to be tested against spore concentrations of nominally 100 times previous testing levels. Even so, STERIPLEX® Health Care passed all testing in record times. EPA Registration #84545-5 was issued to sBioMed™ November 2, 2009.

STERIPLEX® HEALTH CARE is registered as a broad spectrum Sterilant/Sporicide, Tuberculocide, and Bactericide.

While the current EPA registration of STERIPLEX® HEALTH CARE designates use as a hard surface sterilant, future applications of the safe STERIPLEX® technologies could include uses in state-of-the-art disinfection products for hospitals, schools, food processing, and antimicrobial cleaning products and even topical surgical prep and burn center treatments.
Seven U.S. patents have already been issued to sBioMed® and seven more U.S. patents are being processed for issuance. All patents have been filed globally.

Presence of Borrelia burgdorferi in endomyocardial biopsies

Full article:

http://www.springerlink.com/content/b8x4742136623114/

Excerpt:

Abstract Dilated cardiomyopathy (DCM) represents the third most common cause of heart failure and the most frequent cause of heart transplantation. Infectious, mostly viral, and autoimmune mechanisms, together with genetic abnormalities, have been reported as three major causes of DCM. We hypothesized that Lyme disease (LD), caused by spirochete Borrelia burgdorferi (Bb), might be an important cause of new-onset unexplained DCM in patients living in a highly endemic area for LD such as the Czech Republic.

Ontario wine maverick Gabe Magnotta dies

To read the full article:

http://www.stcatharinesstandard.ca/ArticleDisplay.aspx?e=2247054

Posted By MONIQUE BEECH , STANDARD STAFF
January 5, 2010

Excerpts…
In the Ontario wine industry, Gabe Magnotta was a maverick. Continued

The chemokine CXCL13 in acute neuroborreliosis

OBJECTIVE: Recent studies have suggested an important role of the B-cell chemoattractant CXCL13 in acute neuroborreliosis (NB). Our aim was to confirm the diagnostic role of CXCL13 and to evaluate its relevance as a therapy response and disease activity marker in NB. Continued

Borrelia burgdorferi antigens in a mouse model

HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a
mouse model of self-perpetuating arthritis.

Iliopoulou BP, Guerau-De-Arellano M, Huber BT.

Tufts University, Boston, Massachusetts.

OBJECTIVE: Arthritis is a prominent manifestation of Lyme disease, which is
caused by infection with Borrelia burgdorferi (Bb). Chronic Lyme arthritis
persisting even after antibiotic treatment is linked to HLA-DRB1*0401 (DR4) and
related alleles. In contrast, patients whose Lyme arthritis resolves within 3
months postinfection show an increased frequency of HLA-DRB1*1101 (DR11). The
aim of this study was to analyze the underlying mechanism by which HLA-DR
alleles confer genetic susceptibility or resistance to antibiotic-refractory
Lyme arthritis. Continued

Maternal Lyme borreliosis and pregnancy outcome


Int J Infect Dis. 2009 Nov 17. [Epub ahead of print]


Lakos A, Solymosi N.

The Center for Tick-borne Diseases, Visegrádi 14, Budapest, H-1132, Hungary.

BACKGROUND: There is disagreement regarding whether Lyme borreliosis is associated with adverse pregnancy outcome.

METHODS: We performed a review of the data from 95 women with Lyme borreliosis during pregnancy, evaluated at the Center for Tick-borne Diseases, Budapest over the past 22 years.

RESULTS: Treatment was administered parenterally to 66 (69.5%) women and orally to 19 (20%). Infection remained untreated in 10 (10.5%) pregnancies.

Adverse outcomes were seen in 8/66 (12.1%) parentally treated women, 6/19 (31.6%) orally treated women, and 6/10 (60%) untreated women. In comparison to patients treated with antibiotics, untreated women had a significantly higher risk of adverse pregnancy outcome (odds ratio (OR) 7.61, p=0.004).

While mothers treated orally had an increased chance (OR 3.35) of having an adverse outcome compared to those treated parenterally, this difference was not statistically significant (p=0.052). Erythema migrans did not resolve by the end of the first antibiotic course in 17 patients.

Adverse pregnancy outcome was more frequent among these ‘slow responder’ mothers (OR 2.69), but this was not statistically significant (p=0.1425). Loss of the pregnancy (n=7) and cavernous hemangioma (n=4) were the most prevalent adverse outcomes in our series.
The other complications were heterogeneous.

CONCLUSION: Our results indicate that an untreated maternal Borrelia burgdorferi s.l. infection may be associated with an adverse outcome, although bacterial invasion of the fetus cannot be proven.

It appears that a specific syndrome representing ‘congenital Lyme borreliosis’ is unlikely.

PMID: 19926325 [PubMed – as supplied by publisher]

Clinical Judgment in the Diagnosis and Treatment of Lyme Disease

Clinical practice guidelines are increasing in number. Unfortunately,
when scientific evidence is uncertain, limited, or evolving, as is often
the case, conflict often arises between guideline committees and
practicing physicians, who bear the direct responsibility for the care of
individual patients. The 2006 Infectious Diseases Society of America
guidelines for Lyme disease, which have limited scientific support,
could, if implemented, limit the clinical discretion of treating physicians
and the treatment options available to patients

Introduction

Clinical practice guidelines are now ubiquitous throughout the
United States. The National Guidelines Clearing House, under the
category “diseases,” currently lists 2,126 separate guidelines on its
web site. Clinical guidelines are intended to assist physicians in
patient care by clearly communicating the results of the guideline
committees’ evaluation of available therapeutic options. However,
the processes by which individual guidelines are constructed may be
less clear, leading to disagreements between the issuing committee
and the physicians who treat patients-physicians who may well be
as experienced and knowledgeable as the guideline committee. Continued

Association of Mycoplasmal Infections with Malignant Progression, Relapse and Stage in Breast Cancer

Association of Mycoplasmal Infections with Malignant Progression, Relapse and Stage in Breast Cancer Patients

Intracellular bacterial infections have historically been proposed as a cause of cancer [1,2].  Although bacterial involvement in malignant transformation and its reversal with antibiotic treatment have been demonstrated in animal models [3], there are few examples of direct involvement of bacteria in clinical transformation of malignant cells [4].  It seems more likely that the release of Reactive Oxygen Species (ROS) and other genotoxic molecules by intracellular bacteria play a role in progression to malignancy rather than the inception of cancer or transformation [5].  Reports in the literature indicate that over one-half of ovarian cancer patients have mycoplasmal infections in their tumors [6], and the incidence of infection in ovarian cancer was related to stage and survival [7].  Some results have been questioned on the basis of contamination in tissue culture [8], but most studies did not use culture procedures.  Therefore, we examined breast cancer patients to determine if there was a relationship between systemic mycoplasmal infections and progression of their breast cancers.  Examination of breast cancer patients showed mycoplasmal infections inside blood leukocytes (~50%+) not blood plasma or serum.  The most common species found were M. fermentans, M. pneumoniae and M. genitalium.  In contrast, in healthy adults the incidence of these species was low [9].  We found an association between stage, progression (measured by relapse after surgery) and presence of mycoplasmal infection(s) (P<0.001) in breast cancer.  The results suggest that intracellular mycoplasmal infections known to be associated with malignant progression are significantly related to progression and relapse due to metastasis of breast cancer.

Prof. Garth L. Nicolson

American Academy of Environmental Medicine 2005 Annual Meeting

The Institute for Molecular Medicine, Email: gnicolson@immed.org

 References
 1. Nuzum JW. Surg Gynecol Obstet 1925; 11:343-353.

2. Plata et al. J Infect Dis 1973; 128:588-598

3. Tsai et al. PNAS 1995; 92:10197-10201.

4. Feng et al. Mol Cell Biol 1999; 19:7995-8002.

5. Nicolson GL. JANA 2003; 6(3):22-28.

6. Chan et al. Gynecol Oncol. 1996; 63(2):258-260.

7. Camolai N. Can J Microbiol 2001; 47(8):691-697.

8. Quirk et al. Gynecol Oncol. 2001; 83(3):560-562.

9. Nicolson  et al.  J Chronic Fatigue Syndr 2000; 6(3):23-39.